| Autor: |
Oguz F; Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique, Brussels, UCLouvain, Belgium., Demoulin N; Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique, Brussels, UCLouvain, Belgium., Thissen JP; Institut de Recherche Expérimentale et Clinique, Brussels, UCLouvain, Belgium.; Division of Endocrinology, Cliniques universitaires Saint-Luc, Brussels, Belgium., Jadoul M; Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique, Brussels, UCLouvain, Belgium., Morelle J; Division of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique, Brussels, UCLouvain, Belgium. |
| Abstrakt: |
Chronic kidney disease (CKD) is a major public health problem, increasing the risk of cardiovascular events and death and potentially leading to kidney failure. Novel drugs that slow the progression of this non-communicable disease are therefore urgently needed. Initially developed as glucose-lowering drugs, inhibitors of the sodium-glucose cotransporter 2 (SGLT2) drastically reduce the overall mortality and cardiovascular events and slow the progression of CKD. Kidney protection conferred by SGLT2 inhibitors is independent from the presence of diabetes, observed on top of renin-angiotensin system inhibition and consistent across a wide range of categories of glomerular filtration rate and albuminuria. The mechanisms through which SGLT2 inhibitors improve kidney outcomes are likely multifactorial. Inhibition of SGLT2 in the kidney proximal tubule results in natriuresis and glucosuria, with beneficial effects on metabolic control, blood pressure and body weight. In addition, SGLT2 inhibitors also improve intraglomerular hemodynamics, podocyte integrity, cell metabolism, and erythropoiesis and reduce hypoxia, oxidative stress, sympathetic nervous activity, inflammation and fibrosis. The major impact of SGLT2 inhibitors on kidney outcomes, along with the excellent safety profile of this new class of drugs, open novel avenues for the treatment of CKD in patients with and without diabetes. |
